Article By:
Kayla Schiffer
Monday, July 17, 2017 12:15 PM EDT
Immune Pharmaceuticals is gearing up for its split into two pure play companies with new patent filings, strategic deals for commercialization, and the initiation of new clinical trials to support its wide-ranging pipeline.
Immune Pharma To Unlock Value And Create Two Separate Pure Play Companies; Cytovia, Immune
Only time will tell if this is good for $IMNP.
Who Are The Next Acquisition Targets In Dermatology?
I've had my eye on $IMNP lately but it's hard to find coverage on this stock.